Market Closed -
OTC Markets
03:50:00 2024-05-31 pm EDT
5-day change
1st Jan Change
0.0037
USD
+7.25%
+5.71%
-78.86%
Sales 2009
0.01
Sales 2010
0.04
Capitalization
7.45M
Net income 2009
-
Net income 2010
-7M
EV / Sales 2009
325,315,067
x
Net Debt
2009
924K
Net Debt
2010
328K
EV / Sales 2010
210,445,953
x P/E ratio 2009 *
-
P/E ratio 2010
-0.29
x
Employees
-
Yield 2009 *
-
Yield 2010
-
Free-Float
100%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Enzolytics, Inc. Announces Formation of Marketing Company in Partnership with Third Coast Fulfillment LLC
May. 02
CI
Enzolytics, Inc. Announces Board Changes
Mar. 25
CI
Enzolytics, Inc Appoints Diana Zhabilov as Chief Financial Officer
Mar. 25
CI
Enzolytics, Inc Appoints Steven Sharabura as Chief Executive Officer
Mar. 25
CI
Enzolytics Offers Update on Virogentics, Inc ITV-1 African Project
23-06-26
CI
Enzolytics, Inc. Provides Update on Clinical Trials
23-04-21
CI
Biogenysis, Inc. & Virogentics, Inc. executed a non-binding term sheet to acquire Sagaliam Acquisition Corp. from Lighthouse Investment Partners, LLC, Enzolytics, Inc., Sagaliam Sponsor LLC, GLD Sponsor Member, LLC, AHG Equities LLC and others for $450 million in a reverse merger transaction.
23-04-16
CI
Enzolytics Announces Preliminary Results of GLP Toxicology Study for its anti-HIV Therapeutic ITV-1 and Production of ITV-1 for Initiation of Registration in Africa
23-02-08
CI
Enzolytics to Develop Feline Monoclonal Antibodies
23-01-03
CI
Enzolytics, Inc. Announces U.S. Distribution of IPF Immune(TM) and Progress in each of its Therapeutic Platforms
22-12-13
CI
Enzolytics, Inc. Announces Expansion of Production of Its Monoclonal Antibody Therapeutics and Marketing of IPF Immune
22-11-16
CI
Enzolytics, Inc. Appoints Dr. Kirsten Bischof to Its Advisory Board
22-10-24
CI
Enzolytics Inc. Reports Successful Completion of an MTD Tolerability Study of Its ITV-1 anti-HIV Therapeutic Leading to the Start of a 28-day GLP Toxicology Study
22-10-05
CI
Enzolytics Inc. Announces Collaboration with Abveris to Discover Monoclonal Antibodies
22-09-16
CI
Enzolytics Inc. and Samsung Biologics Co., Ltd. Announce Development and Manufacturing Agreement
21-10-07
CI
More news
Stocks Under 5¢ Watch Now! CLNV, HNRC, HALB, ENZC, RSHN
Mar. 28
AQ
RushNet (OTC: RSHN) and Royal Caridea Join Forces to Transform Aquaculture Harvesting Shrimp and more...SPZI, HALB, ENZC, HNRC
Mar. 12
AQ
Stocks Under 5¢ To Watch Now! HNRC, HALB, ENZC, SNNC, SPZI
Mar. 01
AQ
OTC Stocks to Watch in February: CLNV, HNRC, ENZC, GEVI, PBIO
Feb. 07
AQ
"Exploring Market Opportunities Stocks to Watch Under 5¢ Now: CLNV, ENZC, HNRC, HALB, SPZI"
Jan. 25
AQ
More press releases
1 day +7.25%
1 week +5.71%
1 month -17.78%
3 months -78.86%
6 months -85.08%
Current year -78.86%
More quotes
Managers
Title Age Since
Chairman
57
17-06-15
Members of the board
Title Age Since
Chairman
57
17-06-15
More insiders
Date
Price
Change
Volume
24-05-31
0.0037
+7.25%
2,902,586
24-05-30
0.00345
+1.47%
6,411,152
24-05-29
0.0034
-17.07%
46,630,100
24-05-28
0.0041
+17.14%
26,182,087
Delayed Quote
OTC Markets, May 31, 2024 at 03:50 pm EDT
More quotes
Enzolytics, Inc. is a drug development company. The Company is engaged in the commercialization of its proteins and monoclonal antibodies for the treatment of debilitating infectious diseases. Its patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF) for the treatment of human immunodeficiency virus/ acquired immunodeficiency syndrome (HIV/AIDS). It has a technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases which is being employed to produce monoclonal antibody therapeutics for treating the Coronavirus (SARS-CoV-2), HIV-1 and the Feline Leukemia virus. The Company also plans to produce mAbs targeting many other viruses, including HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA).
More about the company
1st Jan change
Capi.
-78.86% 12.45M +11.91% 118B +11.60% 106B -4.68% 24.28B -0.12% 21.96B -9.28% 18.16B -42.12% 16.37B -17.47% 15.56B +2.77% 13.63B +34.58% 12.27B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1